NASDAQ: BYSI · Life Sciences · 7 alerts · CIK 1677940
Share price
$0.5788Close, Nov 16
Market cap
$24M
Shares outstanding
41.41MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BeyondSpring Inc. filings on SEC EDGAR ↗
BeyondSpring Inc. reported a significant net income of $50.5 million for the quarter ended September 30, 2026, primarily driven by a $53.7 million gain on the sale of subsidiary interests and the deconsolidation of discontinued operations. Despite this one-time gain, the company continues to experience operating losses from continuing operations, totaling $2.1 million for the quarter, as it remains in the development stage with no revenue.
BeyondSpring reported Q3 2026 financial results and highlighted that the FDA granted Fast Track designation for Plinabulin in combination with docetaxel for certain NSCLC patients. The company also completed a strategic transaction with Biolin to fund approximately half of the enrollment for the Phase 3 DUBLIN-4 trial.
Term
Q3 2026
“The FDA’s Fast Track designation underscores the significant unmet need for new treatment options for NSCLC patients without AGA and progressing after immune checkpoint inhibitor therapy, where docetaxel is still the standard of care.”
Min Qiu, Chief Executive Officer of BeyondSpring
“With an FDA-aligned Phase 3 design and a strategic transaction with Biolin to support approximately half of DUBLIN-4’s planned 442-patient enrollment, generating quality data from China, we remain focused on advancing the study toward its prespecified interim analysis at 221 progression-free survival events.”
BeyondSpring Inc. held its 2026 annual meeting of shareholders on October 13, 2026, with approximately 50.84% of outstanding shares represented. Shareholders ratified the appointment of CBIZ CPAs P.C. as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
BeyondSpring Divestiture to Biolin Investment Limited
BeyondSpring Inc. completed the sale of its entire issued share capital in BeyondSpring Ltd. to Biolin Investment Limited, effectively divesting its interests in Dalian Wanchunbulin Pharmaceuticals and SEED Therapeutics. The transaction was for non-cash consideration, consisting of a strategic collaboration where the investor funds and completes the China portion of the DUBLIN-4 Phase 3 clinical trial. BeyondSpring retains rights to the clinical data generated from the trial and a potential equity clawback if enrollment targets are not met.
BeyondSpring Inc. received a deficiency notice from Nasdaq on September 29, 2026, because its market value of listed securities (MVLS) fell below the $35 million minimum requirement for 30 consecutive business days. The company has 180 calendar days, or until March 29, 2027, to regain compliance by maintaining a MVLS of at least $35 million for ten consecutive business days. The notice does not result in immediate delisting, and the company's ordinary shares continue to trade on the Nasdaq Capital Market.
BeyondSpring Divestiture to Biolin Investment Limited
BeyondSpring entered into a definitive agreement to sell its majority equity interest in its Chinese subsidiary, Bulin, to Biolin Investment Limited. In exchange for the equity, the investor will fund and conduct the China portion of the global Phase 3 DUBLIN-4 trial for Plinabulin, which is expected to cover approximately 50% of the total trial enrollment.
BeyondSpring Inc. received a deficiency notice from Nasdaq on September 17, 2026, because its ordinary shares closed below the $1.00 minimum bid price for 30 consecutive business days. The company has 180 calendar days, or until March 16, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days.